Publikationen

1. Implications of monoclonal gammopathy and isoelectric focusing pattern 5 on the free light chain kappa diagnostics in cerebrospinal fluid.
   Hannich M*, Konen F*, Gag K, Alkhayer A, Türker S, Budde K, common.et_al
   CLINICAL CHEMISTRY AND LABORATORY MEDICINE
2. Preferences on treatment decision making in sarcoma patients. Prevalence and associated factors - Results from the PROS
   Salm H*, Schuler M, Hentschel L, Richter S, Hohenberger P, Kasper B, common.et_al
   Oncology Research and Treatment
3. Weather-Related Factors and Patient-Reported Outcomes (PROs) in Cancer Patients: Results from the ExPRO Study.
   Salm H*, Eichler M, Bahr J, Andreou D, Schmidt C, Uhlig S, common.et_al
   CANCER INVESTIGATION
4. Dietary Diversity, Rather Than Quality, Parallels a Reduction in Metabolic Syndrome and a Favorable Gut Microbiome: The Dietary Diversity Score.
   Wiese M*, Frost F, Bahls M, von Rheinbaben S, Rühlemann M, Bang C, common.et_al
   Journal of the American Nutrition Association
5. Metastatic melanoma presenting with leucoerythroblastic blood film.
   Zaninetti C*, Einweg M, Almann A, Schwarzer A
   BRITISH JOURNAL OF HAEMATOLOGY

1. Comparison of inpatient and outpatient palliative sedation practice - A prospective observational study.
   Buchhold B*, Jülich A, Glöckner F, Neumann T, Schneidewind L, Schmidt C, common.et_al
   Palliative & Supportive Care
2. FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN)
   Isfort S*, von Bubnoff N, Al-Ali H, Becker H, Götze T, le Coutre P, common.et_al
   ANNALS OF HEMATOLOGY
3. Geriatric Assessment of Older Patients Receiving Trabectedin in First-Line Treatment for Advanced Soft Tissue Sarcomas: The E-TRAB Study from The German Interdisciplinary Sarcoma Group (GISG-13).
   Kasper B*, Pink D, Rothermundt C, Richter S, Augustin M, Kollar A, common.et_al
   Cancers
4. Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy.
   Masetti M*, Al-Batran S, Goetze T, Thuss-Patience P, Knorrenschild J, Goekkurt E, common.et_al
   INTERNATIOAL JOURNAL OF CANCER
5. Eosinophilia as Monitoring Parameter for Chronic Graft-versus-Host Disease and Vitamin D Metabolism as Monitoring Parameter for Increased Infection Rates in Very Long Term Survivors of Allogeneic Stem Cell Transplantation - A Prospective Clinical Study
   Neumann T*, , Schneidewind L, Krüger W
   BioMed
6. Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial
   Pink D, Uhlig S*, Salm H
   SUPPORTIVE CARE IN CANCER
7. Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial
   Pink D
   Lancet Gastroenterology & Hepatology
8. Regional hyperthermia for soft tissue sarcoma - a survey on current practice, controversies and consensus among 12 European centers.
   Roohani S*, Ehret F, Beck M, Veltsista D, Nadobny J, Zschaeck S, common.et_al
   INTERNATIONAL JOURNAL OF HYPERTHERMIA
9. How Do Quality of Life (QoL) and Symptom Burden Evolve in Inpatient Palliative Care (PC) Patients following One Week of Care in a Specialized Palliative Care Unit (PCU)? A Comparison of Two Groups, with One Receiving Specialized Outpatient Palliative Care Prior to Admission
   Salm H*, Uhlig S, Pink D
   Cancers
10. Antileukaemic rescue by dose-dense donor-lymphocyte infusions in T-PLL after allogeneic stem cell transplantation - a case report.
    Späth C*, Neumann T, Krüger W
    Ann Heamatology
11. Geschlechterunterschiede in der ambulanten Versorgung von Menschen mit chronischer Nierenkrankheit
    Stracke S*, Töpfer P, Ittermann T, Dabers T, Kuschnereit R, Freiin von Rheinbaben S, common.et_al
    Nephrologie
12. Ramucirumab, Avelumab, and Paclitaxel as Second-Line Treatment in Esophagogastric Adenocarcinoma: The Phase 2 RAP (AIO-STO-0218) Nonrandomized Controlled Trial.
    Thuss-Patience P*, Högner A, Goekkurt E, Stahl M, Kretzschmar A, Götze T, common.et_al
    JAMA Network Open
13. Inflammatory stress determines the need for chemotherapy in patients with HER2-positive esophagogastric adenocarcinoma receiving targeted and immunotherapy.
    Tintelnot J*, Paschold L, Goekkurt E, Schultheiss C, Matschl U, Santos Cruz M, common.et_al
    Cancer Immunology Research
14. Aggregates of nonmuscular myosin IIA in erythrocytes associate with GATA1- and GFI1B-related thrombocytopenia.
    Zaninetti C*, Rivera J, Vater L, Ohlenforst S, Leinøe E, Böckelmann D, common.et_al
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS
15. Immunofluorescence microscopy on the blood smear identifies patients with myeloproliferative neoplasms.
    Zaninetti C*, Vater L, Kaderali L, Crodel C, Schnöder T, Fuhrmann J, common.et_al
    LEUKEMIA
16. High TSH and low FT3 levels are associated with chronic kidney disease in three population-based studies from Germany
    Stracke S*, Freiin von Rheinbaben S, Völzke H, Gollasch M, König M, Steinhagen-Thiessen E, common.et_al
    Kidney International Reports

Cardiomyocyte peroxisome proliferator-activated receptor α prevents septic cardiomyopathy via improving mitochondrial function.
Zhu X*, Wang X, Jiao S, Liu Y, Shi L, Xu Q, common.et_al
Acta Pharmaceutica Sinica B

Pomalidomide combinations are a safe and effective option after daratumumab failure.
Brioli A*, Gengenbach L, Mancuso K, Binder M, Ernst T, Heidel F, common.et_al
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
Eichhorst B*, Niemann C, Kater A, Fürstenau M, von Tresckow J, Zhang C, common.et_al
NEW ENGLAND JOURNAL OF MEDICINE
[PubMed]
 
Health related Quality of Life over time in German sarcoma patients. An analysis of associated factors - results of the PROSa study.
Eichler M*, Hentschel L, Singer S, Hornemann B, Richter S, Hofbauer C, common.et_al
Frontiers in Endocrinology

Cell fate determinant Llgl1 is required for propagation of acute myeloid leukemi
Eifert T*, Hsu C, Becker A. L. , Graessler S. , Horne A., Bemmann F. , common.et_al
LEUKEMIA
 
[Differences due to socio-economic status, genetic background and sex in cancer and precision medicine - An intersectional approach to close the care gap for marginalized groups].
Engelhardt M*, Brioli A, von Lilienfeld-Toal M
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT

Antimicrobial Prophylaxis in Robot-Assisted Laparoscopic Radical Prostatectomy: A Systematic Review.
Falkensammer E*, Erenler E, Johansen T, Tzelves L, Schneidewind L, Yuan Y, common.et_al
Antibiotics-Basel

AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants.
Giesen N*, Busch E, Schalk E, Beutel G, Rüthrich M, Hentrich M, common.et_al
EUROPEAN JOURNAL OF CANCER

Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM.
Goetze T*, Hofheinz R, Gaiser T, Schmalenberg H, Strumberg D, Goekkurt E, common.et_al
INTERNATIONAL JOURNAL OF CANCER

A digital twin model for evidence-based clinical decision support in multiple myeloma treatment.
Grieb N*, Schmierer L, Kim H, Strobel S, Schulz C, Meschke T, common.et_al
Health Informatics Journal

Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms.
Hinze A*, Rinke J, Crodel C, Möbius S, Schäfer V, Heidel F, common.et_al
BRITISH JOURNAL OF HAEMATOLOGY

Digital health information on surgical treatment options for overactive bladder is underrepresented.
Hüsch T*, Ober S, Haferkamp A, Schneidewind L, Saar M, Kranz J
World Journal Urologie

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia.
Issa G*, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, common.et_a
NATUREl

Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial.
Jones J*, Cairns D, Menzies T, Pawlyn C, Davies F, Sigsworth R, common.et_al
EClinicalMedicine

Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415).
Lorenzen S*, Schwarz A, Pauligk C, Goekkurt E, Stocker G, Knorrenschild J, common.et_al
BMC CANCER

Associations of spleen volume with markers of blood count and lipid profile in a large population-based study
Naeem M*, Ittermann T, Markus M, Mousa M, Herder L, Bülow R, common.et_al
UPSALA JOURNAL OF MEDICAL SCIENCES

Identification of Kazal Inhibitor Scaffolds with Identical Canonical Binding Loops and Their Effects on Binding Properties.
Nagel F*, Susemihl A, Eulberg T, Delcea M
BIOCHEMISTRY

Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study.
Niederwieser D*, Lang T, Krahl R, Heinicke T, Maschmeyer G, Al-Ali H, common.et_al
ANNALS OF HEMATOLOGY

Identification of Kazal Inhibitor Scaffolds with Identical Canonical Binding Loops and Their Effects on Binding Properties.
Nagel F*, Susemihl A, Eulberg T, Delcea M
BIOCHEMISTRY

Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study.
Niederwieser D*, Lang T, Krahl R, Heinicke T, Maschmeyer G, Al-Ali H, common.et_al
ANNALS OF HEMATOLOGY
 
Thirty-Year-Old Male Patient with Non-Seminoma and Coincidental Rectal Cancer.
Nolting J*, Dräger D, Hakenberg O, Schneidewind L
UROLOGIA INTERNATIONALIS

Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.
Palandri F*, Breccia M, Mazzoni C, Auteri G, Elli E, Trawinska M, common.et_al
CANCER

MEN1 mutations mediate clinical resistance to menin inhibition.
Perner F*, Stein E, Wenge D, Singh S, Kim J, Apazidis A, common.et_al
NATURE

Controversies in the management of patients with soft tissue sarcoma: Recommendations of the Conference on State of Science in Sarcoma 2022.
Rothermundt C*, Andreou D, Blay J, Brodowicz T, Desar I, Dileo P, common.et_al
EUROPEAN JOURNAL OF CANCER

Effects of body mass index on the immune response within the first days after stroke in humans.
Ruhnau J*, Heuer C*, Witt C, Ceesay S, Schulze J, Gross S, common.et_al
Neurol Res Pract

Effects of body mass index on the immune response within the first days after major stroke in humans
Ruhnau J*, Heuer C, Wittmann C, Ceesay S, Schulze J, Gross S, common.et_al
Neurological research and practice

Evaluation of electronic patient-reported outcome assessment in inpatient cancer care: a fesibility study
Salm H*, Hentschel L, Eichler M, Pink D, Fuhrmann S, Kramer M, common.et_al
SUPPORTIVE CARE IN CANCER

Evaluation of electronic patient-reported outcome assessment in inpatient cancer care: a feasibility study.
Salm H*, Hentschel L, Eichler M, Pink D, Fuhrmann S, Kramer M, common.et_al
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Diagnosis and treatment of MPN in real life: exploratory and retrospective chart review including 960 MPN patients diagnosed with ET or MF in Germany.
Schmidt A*, Bernhardt C, Bürkle D, Fries S, Hannig C, Jentsch-Ullrich K, common.et_al
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Gender-specific outcomes in immune checkpoint inhibitor therapy for advanced or metastatic urothelial cancer: a systematic review and meta-analysis.
Schneidewind L*, Kiss B, Zengerling F, Borkowetz A, Graf S, Kranz J, common.et_al
CANCER RESEARCH

[Antibiotics for asymptomatic bacteriuria in kidney transplant patients-a commentary on the Cochrane review].
Schneidewind L*
Urologie

Practice Patterns in Fournier's Gangrene in Europe and Implications for a Prospective Registry Study.
Schneidewind L*, Kiss B, Stangl F, Tandogdu Z, Wagenlehner F, Johansen T, common.et_al
Antibiotics-Basel

Prospective Evaluation of Health-Related Quality of Life in Patients with Metastatic Urothelial Carcinoma Undergoing Immunotherapy with Pembrolizumab: Symptom Burden Can Predict Survival.
Schneidewind L*, Dräger D, Roßberg V, Nolting J, Hakenberg O
UROLOGIA INTERNATIONALIS

[Erratum to: Extended vs. standard lymphadenectomy for the treatment of urothelial carcinoma of the bladder in patients undergoing radical cystectomy].
Schneidewind L*, Kiss B
Urologie

Erfahrungen von HausärztInnen mit COVID-19 und der Pandemie – ein Survey nach der ersten Pandemiewelle im März/April 2020 [General Practitioners' Experiences with COVID-19: a Survey After the First Wave of the Pandemic in March/April 2020].
Schrader H*, Borgulya G, Parisi S, Joos S, Kaduszkiewicz H, Barzel A, common.et_al
GESUNDHEITSWESEN

Dynamic DNA methylation reveals novel cis-regulatory elements in mouse hematopoiesis.
Schönung M*, Hartmann M, Krämer S, Stäble S, Hakobyan M, Kleinert E, common.et_al
EXPERIMENTAL HEMATOLOGY

Patients receiving allogeneic haematopoietic stem-cell transplantation and clinical outcomes after early access to palliative care.
Späth C*, Neumann T, Schmidt C, Heidel F, Krüger W
Lancet Haematology

[Do we need to treat asymptomatic bacteriuria in immunocompromised patients? : A rapid review].
Stangl F*, Godly J, Kranz J, Neumann T, Schneidewind L
Urologie

Non-Antibiotic Prophylaxis for Recurrent UTIs in Neurogenic Lower Urinary Tract Dysfunction (NAPRUN): Study Protocol for a Prospective, Longitudinal Multi-Arm Observational Study.
Stangl F*, Schneidewind L, Kiss B, Kranz J, Wagenlehner F, Johansen T, common.et_al
Methods Protoc

[Quo vadis? Antibiotic treatment of asymptomatic bacteriuria during pregnancy].
Stangl F*, Schneidewind L
Urologie

Do or Don't: Results of a Multinational Survey on Antibiotic Prophylaxis in Urodynamics.
Stangl F*, Schneidewind L, Wagenlehner F, Schultz-Lampel D, Baeßler K, Naumann G, common.et_al
Antibiotics-Basel

Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN).
Stegelmann F*, Teichmann L, Heidel F, Crodel C, Ernst T, Kreil S, common.et_al
LEUKEMIA

Cre recombinase expression cooperates with homozygous FLT3 internal tandem duplication knockin mouse model to induce acute myeloid leukemia.
Straube J*, Eifert T, Vu T, Janardhanan Y, Haldar R, von Eyss B, common.et_al
LEUKEMIA

Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models.
Troschke-Meurer S*, Zumpe M, Meißner L, Siebert N, Grabarczyk P, Forkel H, common.et_al
Cancers

Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia.
Tubío-Santamaría N*, Jayavelu A, Schnoeder T, Eifert T, Hsu C, Perner F, common.et_al
Molecular Cancer

Hyperthermia in the treatment of high-risk soft tissue sarcomas: a systematic review.
Veltsista P*, Oberacker E, Ademaj A, Corradini S, Eckert F, Flörcken A, common.et_al
INTERNATIONAL JOURNAL OF HYPERTHERMIA

Effects of Extracorporeal Photopheresis on Quality of Life and the Course of Diseases in Patients With Mycosis Fungoides and Graft-Versus-Host Disease: A Single-Center Analysis.
Vogiatzis R*, Krüger W, Jünger M, Arnold A
Cureus

Immunogenic cell death triggered by impaired deubiquitination in multiple myeloma relies on dysregulated type I interferon signaling
Waad Sadiq Z*, Krüger E*, Brioli A, Al Abdulla R, Cetin G, Schütt J, common.et_al
Frontiers in Immunology

Working situation and burden of work limitations in sarcoma patients: results from the multi-center prospective PROSa study.
Zapata Bonilla S*, Fried M, Singer S, Hentschel L, Richter S, Hohenberger P, common.et_al
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Antiseptic efficacy of two mouth rinses in the oral cavity to identify a suitable rinsing solution in radiation- or chemotherapy induced mucositis
Zwicker P*, Freitag M, Heidel F, Kocher T, Kramer A
BMC Oral Health

Mutations in the plasma cell clone identify mechanism of polyneuropathy in a case of POEMS syndrome associated with Castleman disease and multiple myeloma.
Brioli A*, Wyrwa A, Rüddel U, Yomade O, Lindig U, Franz W, common.et_al
ANNALS OF HEMATOLOGY

Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience.
Chihara D*, Gras L, Zinger N, Kröger N, Mayer J, Passweg J, common.et_al
HAEMATOLOGICA

Validation of myeloproliferative neoplasms associated risk factor RDW as predictor of thromboembolic complications in healthy individuals: analysis on 6849 participants of the SHIP-study
Manz K*, Bahr J, Ittermann T, Döhner K, Koschmieder S, Brümmendorf T, common.et_al
LEUKEMIA

Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib.
Palandri F*, Elli E, Auteri G, Bonifacio M, Benevolo G, Heidel F, common.et_al
Blood Cancer Journa

IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia.
Aubrey B*, Cutler J, Bourgeois W, Donovan K, Gu S, Hatton C, common.et_al
Nature Cancer

Sex-Disaggregated Analysis of Biology, Treatment Tolerability, and Outcome of Multiple Myeloma in a German Cohort.
Brioli A*, Nägler T, Yomade O, Rüthrich M, Scholl S, Frietsch J, common.et_al
Oncology Research and Treatment

Validation of the psychometric properties of a "Modified Version of the Hornheider Screening Instrument" (HSI-MV) using a sample of outpatient and inpatient skin tumor patients.
Buchhold B*, Lutze S, Freyer-Adam J, Jünger M, Ramp M, Konschake W, common.et_al
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT

Context-specific effects of NOX4 inactivation in acute myeloid leukemia (AML).
Demircan M*, Schnoeder T, Mgbecheta P, Schröder K, Böhmer F, Heidel F
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Combined Activity of the Redox-Modulating Compound Setanaxib (GKT137831) with Cytotoxic Agents in the Killing of Acute Myeloid Leukemia Cells.
Demircan M*, Mgbecheta P, Kresinsky A, Schnoeder T, Schröder K, Heidel F, common.et_al
Antioxidants (Basel, Switzerland)

Comparison between thermodilution and Fick methods for resting and exercise-induced cardiac output measurement in patients with chronic dyspnea.
Desole S*, Obst A, Habedank D, Opitz C, Knaack C, Hortien F, common.et_al
Pulmonary Circulation

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Dimopoulos M*, Richardson P, Bahlis N, Grosicki S, Cavo M, Beksaç M, common.et_al
Lancet Haematology

The association of Health-Related Quality of Life and 1-year-survival in sarcoma patients-results of a Nationwide Observational Study (PROSa).
Eichler M*, Singer S, Hentschel L, Richter S, Hohenberger P, Kasper B, common.et_al
BRITISH JOURNAL OF CANCER

Distress in soft-tissue sarcoma and gastrointestinal stromal tumours patients-Results of a German multicentre observational study (PROSa).
Eichler M*, Hentschel L, Singer S, Hornemann B, Hohenberger P, Kasper B, common.et_al
PSYCHO-ONCOLOGY

Histone demethylase KDM4C is a functional dependency in JAK2-mutated neoplasms.
Ernst P*, Schnöder T, Huber N, Perner F, Jayavelu A, Eifert T, common.et_al
LEUKEMIA

BCL11B depletion induces the development of highly cytotoxic innate T cells out of IL-15 stimulated peripheral blood αβ CD8+ T cells
Forkel H*, Grabarczyk P, Depke M, Troschke-Meurer S, Simm S, Hammer E, common.et_al
OncoImmunology

Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Prospective, Multicenter, Phase IV Trial.
Grünwald V*, Pink D, Egerer G, Schalk E, Augustin M, Deinzer C, common.et_al
Cancers

A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis.
Harrison C*, Heidel F, Vannucchi A, Kiladjian J, Hayat A, Passamonti F, common.et_al
HemaSphere

FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group.
Hofheinz R*, Merx K, Haag G, Springfeld C, Ettrich T, Borchert K, common.et_al
JOURNAL OF CLINICAL ONCOLOGY

Transferability of health-related quality of life data of large observational studies to clinical practice - comparing retroperitoneal sarcoma patients from the PROSa study to a TARPS-WG cohort.
Jakob J*, Hentschel L, Richter S, Kreisel I, Hohenberger P, Kasper B, common.et_al
Oncology Research and Treatment

Taz protects hematopoietic stem cells from an aging-dependent decrease in PU.1 activity.
Kim K*, Mura-Meszaros A, Tollot M, Krishnan M, Gründl M, Neubert L, common.et_al
Nature Communications

Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group.
Koschmieder S*, Isfort S, Wolf D, Heidel F, Hochhaus A, Schafhausen P, common.et_al
ANNALS OF HEMATOLOGY

FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO.
Lorenzen S*, Thuss-Patience P, Pauligk C, Gökkurt E, Ettrich T, Lordick F, common.et_al
EUROPEAN JOURNAL OF CANCER

Structural Basis of the Pancreatitis-Associated Autoproteolytic Failsafe Mechanism in Human Anionic Trypsin.
Nagel F*, Susemihl A, Geist N, Möhlis K, Palm G, Lammers M, common.et_al
Nature Communications

Structural and Biophysical Insights into SPINK1 Bound to Human Cationic Trypsin.
Nagel F*, Palm G, Geist N, McDonnell T, Susemihl A, Girbardt B, common.et_al
Nature Communications

MLL::AF9 degradation induces rapid changes in transcriptional elongation and subsequent loss of an active chromatin landscape.
Olsen S*, Godfrey L, Healy J, Choi Y, Kai Y, Hatton C, common.et_al
Molecular Cell

Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis.
Palandri F*, Bartoletti D, Iurlo A, Bonifacio M, Abruzzese E, Caocci G, common.et_al
CANCER

Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review.
Passamonti F*, Heidel F, Parikh R, Ajmera M, Tang D, Nadal J, common.et_al
Future oncology (London, England)

Generation of Inducible Knockout in Transgenic Mouse T Cell Leukemia/Lymphoma Model.
Przybylski G*, Korsak D, Iżykowska K, Nowicka K, Zalewski T, Tubacka M, common.et_al
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Comparison of three different methods to detect bone marrow involvement in patients with neuroblastoma
Schriegel F*, Taschner-Mandl S, Bernkopf M, Grunwald U, Siebert N, Ambros P, common.et_al
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin-MLL Inhibition.
Soto-Feliciano Y*, Sánchez-Rivera F, Perner F, Barrows D, Kastenhuber E, Ho Y, common.et_al
Cancer Discovery

Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical Trial.
Stein A*, Paschold L, Tintelnot J, Gökkurt E, Henkes S, Simnica D, common.et_al
JAMA Oncology

Suppression of MYC by PI3K/AKT/mTOR pathway inhibition in combination with all-trans retinoic acid treatment for therapeutic gain in acute myeloid leukaemia.
Stengel S*, Petrie K, Sbirkov Y, Stanko C, Ghazvini Zadegan F, Gil V, common.et_al
BRITISH JOURNAL OF HAEMATOLOGY

Mutant NPM1 directly regulates oncogenic transcription in acute myeloid leukemia.
Uckelmann H*, Haarer E, Takeda R, Wong E, Hatton C, Marinaccio C, common.et_al
Cancer Discovery

Breakthrough infections in MPN-COVID vaccinated patients.
Barbui T*, Carobbio A, Ghirardi A, Iurlo A, De Stefano V, Sobas M, common.et_al
Blood Cancer Journal

Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysis.
Momotow J*, Bühnen I, Trautmann-Grill K, Kobbe G, Hahn D, Schroers R, common.et_al
BRITISH JOURNAL OF HAEMATOLOGY

Significance of men's health in long-term survivors of allogeneic stem cell transplantation.
Schneidewind L*, Neumann T, Peters N, Kranz J, Probst K, Heidel F, common.et_al
BONE MARROW TRANSPLANTATION

Rhabdomyolysis induced by nelarabine.
Späth C*, Schönau M, Gaubert S, Neumann T, Schmidt C, Heidel F, common.et_al
ANNALS OF HEMATOLOGY

1. Allogeneic stem cell transplantation for mantle cell lymphoma-update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74).
   Krüger WH, Hirt C, Basara N, Sayer HG, Behre G, Fischer T, Grobe N, Maschmeyer G, Neumann T, Schneidewind L, Niederwieser D, Dölken G, Schmidt CA.Ann Hematol. 2021 Apr 8. doi: 10.1007/s00277-021-04506-y. Online ahead of print.PMID: 33829299
2. Unveiling the N-Terminal Homodimerization of BCL11B by Hybrid Solvent Replica-Exchange Simulations.
   Schulig L, Grabarczyk P, Geist N, Delin M, Forkel H, Kulke M, Delcea M, Schmidt CA, Link A.Int J Mol Sci. 2021 Mar 31;22(7):3650. doi: 10.3390/ijms22073650.PMID: 33807484 
3. Implementation of Palliative Care in Clinical Practice in German Units for Allogeneic Stem Cell Transplantation: A Nationwide Survey.
   Krüger W, Buchhold B, Nonnenberg D, Neumann T, Schneidewind L, Schmidt CA.Am J Hosp Palliat Care. 2021 Jan 12:1049909120986963. doi: 10.1177/1049909120986963. Online ahead of print.PMID: 33433238
4. Histone PTM Crosstalk Stimulates Dot1 Methyltransferase Activity.
   Cutler JA, Perner F, Armstrong SA.Trends Biochem Sci. 2021 Apr 17:S0968-0004(21)00067-0. doi: 10.1016/j.tibs.2021.04.001. Online ahead of print.PMID: 33879367
5. Utilization of Interdisciplinary Tumor Boards for Sarcoma Care in Germany: Results from the PROSa Study.
   Eichler M, Andreou D, Golcher H, Hentschel L, Richter S, Hohenberger P, Kasper B, Pink D, Jakob J, Ashmawy H, Hettmer S, Tuchscherer A, Grube M, Heidt V, Jentsch C, Pablik J, Wardelmann E, Kreitner KF, Kneser U, Tonus C, Wimberger P, Schoffer O, Reichardt P, Wartenberg M, Eberlein-Gonska M, Bornhäuser M, Schmitt J, Schuler MK.Oncol Res Treat. 2021 Apr 22:1-9. doi: 10.1159/000516262. Online ahead of print.PMID: 33887740
6. Treatment of Angiosarcoma with Pazopanib and Paclitaxel: Results of the EVA (Evaluation of Votrient^® in Angiosarcoma) Phase II Trial of the German Interdisciplinary Sarcoma Group (GISG-06).
   Pink D, Andreou D, Bauer S, Brodowicz T, Kasper B, Reichardt P, Richter S, Lindner LH, Szkandera J, Grünwald V, Kebenko M, Kirchner M, Hohenberger P.Cancers (Basel). 2021 Mar 11;13(6):1223. doi: 10.3390/cancers13061223.PMID: 33799576 
7. [Treatment of soft tissue sarcomas including GIST - Update 2021].
   Reichardt P, Pink D.Dtsch Med Wochenschr. 2021 Feb;146(3):157-161. doi: 10.1055/a-1170-7731. Epub 2021 Jan 29.PMID: 33513648
8. Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry.
   Al-Batran SE, Hofheinz RD, Reichart A, Pauligk C, Schönherr C, Schlag R, Siegler G, Dörfel S, Koenigsmann M, Zahn MO, Schubert J, Aldaoud A, Höffkes HG, Schulz H, Hahn L, Uhlig J, Blau W, Stauch M, Weniger J, Wolf M, Jacobasch L, Bildat S, Wehmeyer J, Homann N, Trojan J, Waidmann O, Fietz T, Feustel HP, Groschek M, Wierecky J, Waibel K, Mahlmann S, Schwindel U, Peters U, Schuch G, Pink D, Eschenburg H, Wörns MA, Harich HD, von Weikersthal LF, Däßler KU, Behringer DM, Messmann H, Kretzschmar A, Gallmeier E, Forstbauer H, Kunzmann V, Papke J, Büchner-Steudel P, Vehling-Kaiser U, Springfeld C, Vogel A, Ettrich TJ, Schaaf M, Hausen GZ, Götze TO; Arbeitsgemeinschaft Internistische Onkologie (AIO).Int J Cancer. 2021 Mar 15;148(6):1478-1488. doi: 10.1002/ijc.33336. Epub 2020 Oct 23.PMID: 33038277
9. A JAK of all trades: how global phosphoproteomics reveal the Achilles heel of MPNs.
   Schnoeder TM, Perner F, Heidel FH.Mol Cell Oncol. 2021 Jan 30;8(2):1871172. doi: 10.1080/23723556.2020.1871172.PMID: 33855167 Free PMC article.
10. Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome.
    Palandri F, Tiribelli M, Breccia M, Bartoletti D, Elli EM, Benevolo G, Martino B, Cavazzini F, Tieghi A, Iurlo A, Abruzzese E, Pugliese N, Binotto G, Caocci G, Auteri G, Cattaneo D, Trawinska MM, Stella R, Scaffidi L, Polverelli N, Micucci G, Masselli E, Crugnola M, Bosi C, Heidel FH, Latagliata R, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Cavo M, Vianelli N, Bonifacio M, Palumbo GA.Cancer. 2021 Apr 1. doi: 10.1002/cncr.33541. Online ahead of print.PMID: 33794557
11. The Genomic Landscape of Myeloid Malignancies: Options for Pan-myeloid Therapies?
    Heidel FH, Platzbecker U.Hemasphere. 2021 Feb 10;5(3):e537. doi: 10.1097/HS9.0000000000000537. eCollection 2021 Mar.PMID: 33604515 Free PMC article. No abstract available.
12. Impact of comorbidities and body mass index on the outcome of polycythemia vera patients.
    Benevolo G, Elli EM, Bartoletti D, Latagliata R, Tiribelli M, Heidel FH, Cavazzini F, Bonifacio M, Crugnola M, Binotto G, D'Addio A, Tieghi A, Bergamaschi M, Caocci G, Polverelli N, Bossi E, Auteri G, Carmosino I, Catani L, Cuneo A, Krampera M, Lanza F, Lemoli RM, Vianelli N, Breccia M, Palumbo GA, Cavo M, Palandri F.Hematol Oncol. 2021 Feb 15. doi: 10.1002/hon.2843. Online ahead of print.PMID: 33590502
13. Molecular Mechanisms of Senescence and Implications for the Treatment of Myeloid Malignancies.
    Ernst P, Heidel FH.Cancers (Basel). 2021 Feb 4;13(4):612. doi: 10.3390/cancers13040612.PMID: 33557090 Free PMC article. Review.
14. Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis.
    Palandri F, Palumbo GA, Elli EM, Polverelli N, Benevolo G, Martino B, Abruzzese E, Tiribelli M, Tieghi A, Latagliata R, Cavazzini F, Bergamaschi M, Binotto G, Crugnola M, Isidori A, Caocci G, Heidel F, Pugliese N, Bosi C, Bartoletti D, Auteri G, Cattaneo D, Scaffidi L, Trawinska MM, Stella R, Ciantia F, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Iurlo A, Vianelli N, Cavo M, Breccia M, Bonifacio M.Blood Cancer J. 2021 Jan 7;11(1):4. doi: 10.1038/s41408-020-00392-1.PMID: 33414394 Free PMC article. No abstract available.
15. Second primary malignancy in myelofibrosis patients treated with ruxolitinib.
    Polverelli N, Elli EM, Abruzzese E, Palumbo GA, Benevolo G, Tiribelli M, Bonifacio M, Tieghi A, Caocci G, D'Adda M, Bergamaschi M, Binotto G, Heidel FH, Cavazzini F, Crugnola M, Pugliese N, Bosi C, Isidori A, Bartoletti D, Auteri G, Latagliata R, Gandolfi L, Martino B, Scaffidi L, Cattaneo D, D'Amore F, Trawinska MM, Stella R, Markovic U, Catani L, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Vianelli N, Breccia M, Russo D, Cavo M, Iurlo A, Palandri F.Br J Haematol. 2021 Apr;193(2):356-368. doi: 10.1111/bjh.17192. Epub 2020 Nov 21.PMID: 33222197
16. Heikamp EB, Henrich JA, Perner F, Wong EM, Hatton C, Wen Y, Barwe SP, Gopalakrishnapillai A, Xu H, Uckelmann HJ, Takao S, Kazansky Y, Pikman Y, McGeehan GM, Kolb EA, Kentsis A, Armstrong SA. The Menin-MLL1-interaction is a functional dependency in NUP-98 rearranged AML. Blood. 2021 Sep 28:blood.2021012806. doi: 10.1182/blood.2021012806. Online ahead of print. PMID: 34582559 [IF 22.113]
17. Perner F, Schnoeder TM, Xiong Y, Jayavelu AK, Mashamba N, Santamaria NT, Huber N, Todorova K, Hatton C, Perner B, Eifert T, Murphy C, Hartmann M, Hoell JI, Schröder N, Brandt S, Hochhaus A, Mertens PR, Mann M, Armstrong SA, Mandinova A, Heidel FH. YBX1 mediates translation of oncogenic transcripts to control cell competition in AML. Leukemia, 2021 Aug 31. doi: 10.1038/s41375-021-01393-0 [IF 11.528]
18. Gecht J, Tsoukakis I, Kricheldorf K, Stegelmann F, Klausmann M, Griesshammer M, Schulz H, Hollburg W, Göthert JR, Sockel K, Heidel FH, Gattermann N, Maintz C, Al-Ali HK, Platzbecker U, Hansen R, Hänel M, Parmentier S, Bommer M, Pahl HL, Lang F, Kirschner M, Isfort S, Brümmendorf TH, Döhner K, Koschmieder S. Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry. Cancers (Basel). 2021 Aug 13;13(16):4086. doi: 10.3390/cancers13164086. PMID: 34439237 [IF 6.126]
19. Neumann T, Peters N, Kranz J, Dräger DL, Heidel FH, Krüger W, Schneidewind L. Significance of BK Polyomavirus in Long-Term Survivors After Adult Allogeneic Stem Cell Transplantation. Biology 2021, 10, 553. https://doi.org/10.3390/biology10060553 [IF 3.796]
20. Tubio-Santamaria N, Ebstein F, Heidel FH, Krüger E. Immunoproteasome function in normal and malignant hematopoiesis. Cells 2021, 10, 1577. https://doi.org/10.3390/cells10071577 [IF 4.366]
21. Hsu CJ, Miers O, Buschbeck M Heidel FH. Role of Macrohistone H2A Variants in Cancer. Cancers 2021, 13, 3003. https://doi.org/10.3390/cancers13123003 [IF 6.126]
22. Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry. Hernández-Boluda JC, Pereira A, Kröger N, Cornelissen JJ, Finke J, Beelen D, de Witte M, Wilson K, Platzbecker U, Sengeloev H, Blaise D, Einsele H, Sockel K, Krüger W, Lenhoff S, Salaroli A, Martin H, García-Gutiérrez V, Pavone V, Alvarez-Larrán A, Raya JM, Zinger N, Gras L, Hayden P, Czerw T, P McLornan D, Yakoub-Agha I.Am J Hematol. 2021 Oct 1;96(10):1186-1194. doi: 10.1002/ajh.26279. Epub 2021 Jul 8.PMID: 34152630

1. Jayavelu AK, Schnöder TM, Perner F, Herzog C, Meiler A, Krishnamoorthy G, Huber N, Mohr J, Edelmann-Stephan B, Austin R, Brandt S, Palandri F, Schröder N, Isermann B, Edlich F, Sinha AU, Ungelenk M, Hübner CA, Zeiser R, Rahmig S, Waskow C, Coldham I, Ernst T, Hochhaus A, Jilg S, Jost PJ, Mullally A, Bullinger L, Mertens PR, Lane SW, Mann M, Heidel FH. Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms. Nature. 2020 Dec;588(7836):157-163. doi: 10.1038/s41586-020-2968-3. Epub 2020 Nov 25.PMID: 33239784

2. Saliakoura M, Pozzato C, Rossi MS, Heidel FH, Schnöder TM, Baumgartner J, Freigang S, Rimessi A, Pinton P, Felser AD, Nuoffer JM, Spasenija SP, Bubendorf L, Schmid R, Berezowska SA, and Konstantinidou G. PLCgamma1 inhibition mediates the survival of KRAS-mutant lung cancer during hypoxia. Nat Cell Biol. 2020 Oct 19. doi: 10.1038/s41556-020-00592-8.
3. Brandt S, Ballhause TM, Bernhardt A, Becker A, Salaru D, Le-Deffge HM, Fehr A, Fu Y, Philipsen L, Djudjaj S, Müller AJ, Kramann R, Ibrahim M, Geffers R, Siebel C, Isermann B, Heidel FH, Lindquist JA, Mertens PR. Fibrosis and Immune Cell Infiltration Are Separate Events Regulated by Cell-Specific Receptor Notch3 Expression. J Am Soc Nephrol. 2020 Aug 28; ASN.2019121289.
4. Cortes JE, Heidel FH, Fiedler W, Smith BD, Robak T, Montesinos P, Candoni A, Leber B, Sekeres MA, Pollyea DA, Ferdinand R, Ma WW, O'Brien T, O'Connell A, Chan G, Heuser M. Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy. J Hematol Oncol. 2020 Jul 14;13(1):92.
5. Vu T, Straube J, Porter AH, Bywater M, Song A, Ling V, Cooper L, Pali G, Bruedigam C, Jacquelin S, Green J, Magor G, Perkins A, Chalk AM, Walkley CR, Heidel FH, Mukhopadhyay P, Cloonan N, Gröschel S, Mallm JP, Fröhling S, Scholl C, Lane SW. Hematopoietic stem and progenitor cell-restricted Cdx2 expression induces transformation to myelodysplasia and acute leukemia. Nature Commun. 2020 Jun 15;11(1):3021.
6. Crodel CC, Jentsch-Ullrich K, Koschmieder S, Kämpfe D, Griesshammer M, Döhner K, Jost PJ, Wolleschak D, Isfort S, Stegelmann F, Jilg S, Hofmann V, Auteri G, Rachow T, Ernst P, Brioli A, von Lilienfeld-Toal M, Hochhaus A, Palandri F, Heidel FH. Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study. Leukemia. 2020 Jul;34(7):1949-1953.
7. Midic D, Rinke J, Perner F, Müller V, Hinze A, Pester F, Landschulze J, Ernst J, Gruhn B, Matziolis G, Heidel FH, Hochhaus A, Ernst T. Prevalence and dynamics of clonal hematopoiesis caused by leukemia-associated mutations in elderly individuals without hematologic disorders. Leukemia. 2020 Aug;34(8):2198-2205. doi: 10.1038/s41375-020-0869-y.
8. Palandri F, Breccia M, Bonifacio M, Polverelli N, Elli EM, Benevolo G, Tiribelli M, Abruzzese E, Iurlo A, Heidel FH, Bergamaschi M, Tieghi A, Crugnola M, Cavazzini F, Binotto G, Isidori A, Sgherza N, Bosi C, Martino B, Latagliata R, Auteri G, Scaffidi L, Griguolo D, Trawinska M, Cattaneo D, Catani L, Krampera M, Lemoli RM, Cuneo A, Semenzato G, Foà R, Di Raimondo F, Bartoletti D, Cavo M, Palumbo GA, Vianelli N. Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer. 2020 Mar 15;126(6):1243-1252. doi: 10.1002/cncr.32664.
9. Kaiser A, Schmidt M, Huber O, Frietsch JJ, Scholl S, Heidel FH, Hochhaus A, Müller JP, Ernst T. SIRT7: an influence factor in healthy aging and the development of age-dependent myeloid stem-cell disorders. Leukemia. 2020 Mar 25. doi: 10.1038/s41375-020-0803-3
10. Palandri F, Breccia M, Tiribelli M, Bonifacio M, Benevolo G, Iurlo A, Elli EM, Binotto G, Tieghi A, Polverelli N, Martino B, Abruzzese E, Bergamaschi M, Heidel FH, Cavazzini F, Crugnola M, Bosi C, Isidori A, Auteri G, Forte D, Latagliata R, Griguolo D, Cattaneo D, Trawinska M, Bartoletti D, Krampera M, Semenzato G, Lemoli RM, Cuneo A, Di Raimondo F, Vianelli N, Cavo M, Palumbo GA. Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data. Hematol Oncol. 2020 Apr 9. doi: 10.1002/hon.2737.
11. Reich D, Kresinsky A, Müller JP, Bauer R, Kallenbach J, Schnoeder TM, Heidel FH, Fässler R, Mann M, Böhmer FD, Jayavelu AK. SHP1 regulates a STAT6-ITGB3 axis in FLT3ITD-positive AML cells. Leukemia. 2020 May;34(5):1444-1449. doi: 10.1038/s41375-019-0676-5.
12. Austin R, Straube J, Bruedigam C, Pali G, Jacquelin S, Vu T, Green J, Gräsel J, Lansink L, Cooper L, Haque A, Heidel FH, D’Andrea R, Mullally A, Milsom MD, Bywater M, Lane SW. Distinct effects of ruxolitinib vs. interferon-alpha on myeloproliferative neoplasm haematopoietic stem cell populations. Leukemia. 2020 Apr;34(4):1075-1089.

• Al-Batran S*, Homann N, Pauligk C, Goetze T, Meiler J, Kasper S, Kopp H, Mayer F, Haag G, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens U, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F, Behringer D, Heike M, Pink D, Teschendorf C, Löhr C, Bernhard H, Schuch G, Rethwisch V, von Weikersthal L, Hartmann J, Kneba M, Daum S, Schulmann K, Weniger J, Belle S, Gaiser T, Oduncu F, Güntner M, Hozaeel W, Reichart A, Jäger E, Kraus T, Mönig S, Bechstein W, Schuler M, Schmalenberg H, Hofheinz R, on behalf of the Float4-AIO I. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. (Originalartikel)
  LANCET (LONDON, ENGLAND). 2019; 393(10184):1948-1957.
• Hirt C*, Iannazzo S, Chiroli S, McGarry L, le Coutre P, Stenke L, Dahlén T, Lipton J. Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia. (Originalartikel)
  APPLIED HEALTH ECONOMICS AND HEALTH POLICY. 2019; 17(4):555-567.
• Kranz J*, Schlager D, Mühlstädt S, Nagler J, Wagenlehner F, Schneidewind L. [Barriers to guideline adherence : Identification of barriers to guideline adherence using a survey on the AWMF S3 guideline epidemiology, diagnosis, treatment, and management of uncomplicated bacterial, community-acquired urinary tract infections in adult patients]. (Originalartikel)
  DER UROLOGE. AUSG. A. 2019; Jan(8).
• Michallet M*, Dreger P, Sobh M, Koster L, Hoek J, Boumendil A, Scheid C, Fox C, Wulf G, Krüger W, van Gelder M, Corradini P, Russo D, Passweg J, Schoemans H, Bethge W, Schaap N, Cornelissen J, Browne P, Durakovic N, Muller L, Montoto S, Kroger N, Schetelig J, on behalf of the French Cooperative Group for CLL a. Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia. (Originalartikel)
  BONE MARROW TRANSPLANTATION. 2019.
• Neumann T*, Schneidewind L, Weigel M, Plis A, Vaizian R, Schmidt A, Krüger W. Ruxolitinib for Therapy of Graft-versus-Host Disease. (Originalartikel)
  BIOMED RESEARCH INTERNATIONAL. 2019; 2019:8163780.
• Ni M*, Wang L, Yang M, Neuber B, Sellner L, Hückelhoven-Krauss A, Schubert M, Luft T, Hegenbart U, Schönland S, Wuchter P, Chen B, Eckstein V, Krüger W, Yerushalmi R, Beider K, Nagler A, Müller-Tidow C, Dreger P, Schmitt M, Schmitt A. Shaping of CD56 Natural Killer Cells in Patients With Steroid-Refractory/Resistant Acute Graft-vs.-Host Disease via Extracorporeal Photopheresis. (Originalartikel)
  FRONTIERS IN IMMUNOLOGY. 2019; 10:547.
• Samal R*, Sappa P, Gesell Salazar M, Wenzel K, Reinke Y, Völker U, Felix S, Hammer E, Könemann S. Global secretome analysis of resident cardiac progenitor cells from wild type and transgenic heart failure mice: why ambience matters. (Originalartikel)
  JOURNAL OF CELLULAR PHYSIOLOGY. 2019; 234(7):10111-10122.
• Schnabel M*, Wagenlehner F, Schneidewind L. Perioperative antibiotic prophylaxis for stone therapy. (Originalartikel)
  CURRENT OPINION IN UROLOGY.  (open access) 2019; 29(2):89-95.
• Schneidewind L*. [Benefits and risks of early versus late ureteric stent removal after kidney transplantation]. (Originalartikel)
  DER UROLOGE. AUSG. A. 2019; Jan(21).
• Schneidewind L*, Neumann T, Zimmermann K, Weigel M, Schmidt C, Krüger W. Is BK Virus-Associated Cystitis a Generalized Epithelial Disease?. (Originalartikel)
  ACTA HAEMATOLOGICA. 2019; 141(2):65-67.

• Anheuser P*, Mühlstädt S, Kranz J, Schneidewind L, Steffens J, Fornara P. Significance of Hyperbaric Oxygenation in the Treatment of Fournier's Gangrene: A Comparative Study. (Originalartikel)
  UROLOGIA INTERNATIONALIS. 2018; 101(4):467-471.
• Boehm K*, Siegel F, Schneidewind L, Kranz J, Spachmann P, Frank T, Huck N, Imkamp F, Pelzer A. Antibiotic Prophylaxis in Prostate Biopsies: Contemporary Practice Patterns in Germany. (Originalartikel)
  FRONTIERS IN SURGERY. 2018; Jan 24(5):2.
• Buchhold B*, Lutze S, Arnold A, Jülich A, Daeschlein G, Wendler M, Jünger M, Hannich H. Psychosocial distress and desire for support among skin cancer patients - impact of treatment setting. (Originalartikel)
  JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT = JOURNAL OF THE GERMAN SOCIETY OF DERMATOLOGY : JDDG.  (open access) 2018; 16(7):861-872.
• Buchhold B*, Lutze S, Arnold A, Jülich A, Daeschlein G, Wendler M, Jünger M, Hannich H. Psychosoziale Belastung und Unterstützungswunsch von Hauttumorpatienten - Einfluss des Behandlungs-Settings. (Originalartikel)
  JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT = JOURNAL OF THE GERMAN SOCIETY OF DERMATOLOGY : JDDG. 2018; 7(16):861-872.
• Grabarczyk P*, Winkler P, Delin M, Sappa P, Bekeschus S, Hildebrandt P, Przybylski G, Völker U, Hammer E, Schmidt C. The N-terminal CCHC zinc finger motif mediates homodimerization of the transcription factor BCL11B. (Originalartikel)
  MOLECULAR AND CELLULAR BIOLOGY. 2018; 38(5).
• Kranz J*, Schmidt S, Lebert C, Schneidewind L, Mandraka F, Kunze M, Helbig S, Vahlensieck W, Naber K, Schmiemann G, Wagenlehner F. The 2017 Update of the German Clinical Guideline on Epidemiology, Diagnostics, Therapy, Prevention, and Management of Uncomplicated Urinary Tract Infections in Adult Patients: Part 1. (Originalartikel)
  UROLOGIA INTERNATIONALIS. 2018; Jan(17).
• Kranz J*, Schmidt S, Lebert C, Schneidewind L, Mandraka F, Kunze M, Helbig S, Vahlensieck W, Naber K, Schmiemann G, Wagenlehner F. The 2017 Update of the German Clinical Guideline on Epidemiology, Diagnostics, Therapy, Prevention, and Management of Uncomplicated Urinary Tract Infections in Adult Patients. Part II: Therapy and Prevention. (Originalartikel)
  UROLOGIA INTERNATIONALIS. 2018; Mar(14).
• Kranz J*, Schmidt S, Lebert C, Schneidewind L, Schmiemann G, Wagenlehner F. In Reply. (Originalartikel)
  DEUTSCHES ARZTEBLATT INTERNATIONAL. 2018; 115(11):192.
• Kranz J*, Schmidt S, Schneidewind L. Current Evidence on Nonantibiotic Prevention of Recurrent Urinary Tract Infections. (Originalartikel)
  EUROPEAN UROLOGY FOCUS. 2018.
• Kranz J*, Schlager D, Anheuser P, Mühlstädt S, Brücher B, Frank T, Barski D, Mayr R, Lunacek A, Macharia-Nimietz E, Steffens J, Grolle J, Pelzer A, Schneidewind L. Desperate need for better management of Fournier's gangrene. (Originalartikel)CENTRAL EUROPEAN JOURNAL OF UROLOGY. 2018; 71(3):360-365.
• Schneidewind L*, Neumann T, Probst K, Schmidt C, Krüger W. Recovery from hypogonadism and male health in adult allogeneic stem cell transplantation. (Originalartikel)
  EUROPEAN JOURNAL OF HAEMATOLOGY. 2018; Mar(6).
• Schneidewind L*, Neumann T, Schmidt C, Krüger W. Comparison of intravenous or intravesical cidofovir in the treatment of BK polyomavirus-associated hemorrhagic cystitis following adult allogeneic stem cell transplantation-A systematic review. (Originalartikel)
  TRANSPLANT INFECTIOUS DISEASE : AN OFFICIAL JOURNAL OF THE TRANSPLANTATION SOCIETY. 2018; e12914.
• Schneidewind L*. [School-based prevention programmes for adolescents: HIV, sexually transmitted infections, and pregnancy]. (Originalartikel)
  DER UROLOGE. AUSG. A. 2018; May(9).
• Steininger A*, Ebert G, Becker B, Assaf C, Möbs M, Schmidt C, Grabarczyk P, Jensen L, Przybylski G, Port M, Kuß A, Ullmann R. Genome-Wide Analysis of Interchromosomal Interaction Probabilities Reveals Chained Translocations and Overrepresentation of Translocation Breakpoints in Genes in a Cutaneous T-Cell Lymphoma Cell Line. (Originalartikel)
  FRONTIERS IN ONCOLOGY. 2018; 8:183.
• Stentzel U*, Bahr J, Fredrich D, Piegsa J, Hoffmann W, van den Berg N. Is there an association between spatial accessibility of outpatient care and utilization? Analysis of gynecological und general medical care. (Originalartikel)
  BMC HEALTH SERVICES RESEARCH.  (open access) 2018; 18(1):322.
• Wang L*, Ni M, Hückelhoven-Krauss A, Sellner L, Hoffmann J, Neuber B, Luft T, Hegenbart U, Schönland S, Kleist C, Sill M, Chen B, Wuchter P, Eckstein V, Krüger W, Hilgendorf I, Yerushalmi R, Nagler A, Müller-Tidow C, Ho A, Dreger P, Schmitt M, Schmitt A. Modulation of B Cells and Homing Marker on NK Cells Through Extracorporeal Photopheresis in Patients With Steroid-Refractory/Resistant Graft-Vs.-Host Disease Without Hampering Anti-viral/Anti-leukemic Effects. (Originalartikel)
  FRONTIERS IN IMMUNOLOGY. 2018; 9:2207.
• Heidel F*, Al-Ali H, Hirt C, Kämpfe D, Jentsch-Ullrich K, Junghanss C, Nowak R, Schwarzer A, Spohn C, Vucinic V, Hochhaus A, Lange T, OSHO S. Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions. (Letter)
  LEUKEMIA. 2018; 32(9):2085-2087.

• Jülich A*, Spreu T, Buchhold B, Usichenko T. The Impact of Integrated Multidisciplinary Palliative Care Program on Symptoms in Patients at the Palliative Care Ward-An Audit and a Protocol of Prospective Controlled Investigation. (Originalartikel)
  JOURNAL OF PALLIATIVE CARE. 2017. (In Press)
• Barski D*, Gerullis H, Ecke T, Kranz J, Schneidewind L, Leistner N, Queissert F, Mühlstädt S, Grabbert M, Tahbaz R, Pelzer A, Joukhadar R, Klinge U, Boros M, Bader W, Naumann G, Puppe F, Otto T. Registry of implants for the reconstruction of pelvic floor in males and females: A feasibility case series. (Originalartikel)
  INTERNATIONAL JOURNAL OF SURGERY (LONDON, ENGLAND). 2017; 42:27-33.
• Buchhold B*, Arnold A, Hannich H, Lutze S, Jülich A, Winkler M, Bahlmann J, Eggert C, Jünger M. Stationäre Hauttumorpatienten - Psychosoziale Belastung und Unterstützungswunsch. (Originalartikel)
  JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT = JOURNAL OF THE GERMAN SOCIETY OF DERMATOLOGY : JDDG. 2017; 15(8):791-800.
• Buchhold B*, Arnold A, Lutze S, Jülich A, Winkler M, Bahlmann J, Eggert C, Jünger M, Hannich H. Psychosocial distress and desire for support among inpatients with skin cancer. (Originalartikel)
  JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT = JOURNAL OF THE GERMAN SOCIETY OF DERMATOLOGY : JDDG. 2017; 15(8):791-799.
• Busemann C*, Jülich A, Buchhold B, Schmidt V, Schneidewind L, Pink D, Schmidt C, Neumann T, Krüger W. Clinical course and end-of-life care in patients who have died after allogeneic stem cell transplantation. (Originalartikel)
  JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2017.
• Izykowska K*, Przybylski G, Gand C, Braun F, Grabarczyk P, Kuß A, Olek-Hrab K, Torres A, Vermeer M, Zoutman W, Tensen C, Schmidt C. Genetic rearrangements result in altered gene expression and novel fusion transcripts in Sézary syndrome. (Originalartikel)
  ONCOTARGET. 2017; 8(24):39627-39639.
• Kranz J*, Schmidt S, Lebert C, Schneidewind L, Vahlensieck W, Sester U, Fünfstück R, Helbig S, Hofmann W, Hummers E, Kunze M, Kniehl E, Naber K, Mandraka F, Mündner-Hensen B, Schmiemann G, Wagenlehner F. [Epidemiology, diagnostics, therapy, prevention and management of uncomplicated bacterial outpatient acquired urinary tract infections in adult patients : Update 2017 of the interdisciplinary AWMF S3 guideline]. (Originalartikel)
  DER UROLOGE. AUSG. A. 2017; 56(6):746-758.
• Kranz J*, Schmidt S, Lebert C, Schneidewind L, Schmiemann G, Wagenlehner F. Uncomplicated Bacterial Communityacquired Urinary Tract Infection in Adults. (Originalartikel)
  DEUTSCHES ARZTEBLATT INTERNATIONAL. 2017; 114(50):866-873.
• Neumann T*, Plis A, Weigel M, Stracke S, Friesecke S, Stecher S, Schneidewind L, Busemann C, Schmidt C, Krüger W. No Relapse of Calcineurin Inhibitor-Associated Thrombotic Microangiopathy after Discontinuation of Eculizumab. (Originalartikel)
  ACTA HAEMATOLOGICA. 2017; 138(4):194-197.
• Neumann T*, Schneidewind L, Thiele T, Pink D, Schulze M, Schmidt C, Krüger W. No indication of increased infection rates using low-dose alemtuzumab instead of anti-thymocyte globulin as graft-versus-host disease prophylaxis before allogeneic stem cell transplantation. (Originalartikel)
  TRANSPLANT INFECTIOUS DISEASE : AN OFFICIAL JOURNAL OF THE TRANSPLANTATION SOCIETY. 2017.
• Reuß D*, Altenbuchner J*, Mäder U*, Rath H, Ischebeck T, Sappa P, Thürmer A, Guerin C, Nicolas P, Steil L, Zhu B, Feussner I, Klumpp S, Daniel R, Commichau F, Völker U, Stülke J. Large-scale reduction of the Bacillus subtilis genome: Consequences for the transcriptional network, resource allocation, and metabolism. (Originalartikel)
  GENOME RESEARCH. 2017; 27(2):289-299.
• Schneidewind L*, Neumann T, Knoll F, Zimmermann K, Smola S, Schmidt C, Krüger W. Are the Polyomaviruses BK and JC Associated with Opportunistic Infections, Graft-versus-Host Disease, or Worse Outcomes in Adult Patients Receiving Their First Allogeneic Stem Cell Transplantation with Low-Dose Alemtuzumab?. (Originalartikel)
  ACTA HAEMATOLOGICA. 2017; 138(1):3-9.
• Schneidewind L*, Kranz J, Schlager D, Barski D, Mühlsteadt S, Grabbert M, Queissert F, Frank T, Pelzer A. Mulitcenter study on antibiotic prophylaxis, infectious complications and risk assessment in TUR-P. (Originalartikel)
  CENTRAL EUROPEAN JOURNAL OF UROLOGY. 2017; 70(1):112-117.
• Schneidewind L*, Neumann T, Kranz J, Knoll F, Pelzer A, Schmidt C, Krüger W. Nationwide survey of BK polyomavirus associated hemorrhagic cystitis in adult allogeneic stem cell transplantation among haematologists and urologists. (Originalartikel)
  ANNALS OF HEMATOLOGY. 2017; 96(5):797-803.
• Schneidewind L*, Kranz J, Schlager D, Pelzer A. [Nationwide survey among institutes of microbiology in academic medicine : Is the interdisciplinary approach the right way to treat patients with urogenital infections?]. (Originalartikel)
  DER UROLOGE. AUSG. A. 2017; 56(6):779-784.
• Schneidewind L*. [Antibiotic prophylaxis for transrectal prostate biopsy]. (Originalartikel)
  DER UROLOGE. AUSG. A. 2017; 56(1):60-64.
• Schneidewind L*, Neumann T, Zimmermann K, Schmidt C, Krüger W. Urological complications associated with adult allogeneic stem cell transplantation. (Letter)
  AMERICAN JOURNAL OF HEMATOLOGY. 2017.